Bristol Myers licenses for Evotec molecule for $20M; FDA approves Impel's migraine nasal spray Trudhesa
Bristol Myers Squibb has exercised its option with Evotec for EVT8683, a small molecule created by the German biotech to target …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
